BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Treatment
4751 results:

  • 1. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
    Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
    Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [prostate cancer - a disease in transformation].
    Bratt O
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38661575
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Surgical management of rectal cancer with synchronous treatment of prostate cancer.
    Brière R; Martin AG; Letarte F; Fournier FR; Bouchard P; Drolet S
    Langenbecks Arch Surg; 2024 Apr; 409(1):133. PubMed ID: 38642125
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Patterns of Care for Medicare Beneficiaries With Metastatic prostate cancer.
    Filson CP; Richards TB; Ekwueme DU; Howard DH
    Urol Pract; 2024 May; 11(3):489-497. PubMed ID: 38640419
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance.
    Ross AE; Iwata KK; Elsouda D; Hairston J; Russell D; Davicioni E; Proudfoot JA; Shore ND; Schaeffer EM
    JCO Precis Oncol; 2024 Apr; 8():e2300603. PubMed ID: 38635932
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clinical safety and efficacy of microwave ablation for small renal masses.
    Foret A; Haaga CB; Jain S; Baumgartner CO; Escott M; Henderson BR; O'Brien ST; Delacroix SE; Gills JRR; Westerman ME
    Int Braz J Urol; 2024; 50(3):277-286. PubMed ID: 38598830
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
    Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
    BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
    Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
    Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
    Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Association Between Acute Kidney Injury and the Trendelenburg Position Angle During Robot-assisted Radical prostatectomy.
    Masuda H; Amemiya Y; Yagisawa N; Arai T; Yanagisawa M
    Anticancer Res; 2024 Apr; 44(4):1767-1772. PubMed ID: 38538005
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
    Dwina Y; Zaid LSM; Saraswati M; Rachmadi L; Kekalih A; Rahadiani N; Louisa M; Agustina H; Mochtar CA; Hamid ARAH
    Prostate; 2024 Jun; 84(8):738-746. PubMed ID: 38528654
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique.
    Albo G; Gallioli A; Ripa F; De Lorenzis E; Boeri L; Bebi C; Rocchini L; Longo F; Zanetti SP; Turetti M; Piccoli M; Montanari E
    BMC Urol; 2024 Mar; 24(1):64. PubMed ID: 38515053
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review.
    Neerhut T; Grills R; Lynch R; Preece PD; McLeod K
    Urol Oncol; 2024 Jun; 42(6):165-174. PubMed ID: 38503591
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".
    Marvaso G; Corrao G; Repetti I; Lorubbio C; Bellerba F; Zaffaroni M; Vincini MG; Zerini D; Alessi S; Luzzago S; Mistretta FA; Fodor C; Cambria R; Cattani F; Ceci F; Musi G; De Cobelli O; Zilli T; Gandini S; Orecchia R; Petralia G; Jereczek-Fossa BA
    World J Urol; 2024 Mar; 42(1):169. PubMed ID: 38492078
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Exploring the relation of active surveillance schedules and prostate cancer mortality.
    Yang Z; Heijnsdijk EAM; Newcomb LF; Rizopoulos D; Erler NS
    Cancer Med; 2024 Mar; 13(5):e6977. PubMed ID: 38491826
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Compliance With NCCN Guidelines for Evaluation and treatment of Anemia Among Patients With Solid Tumors.
    Hufnagel DH; Bos LM; Brown AJ; Prescott LS
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38489926
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. 25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis.
    Shelton J; Zotow E; Smith L; Johnson SA; Thomson CS; Ahmad A; Murdock L; Nagarwalla D; Forman D
    BMJ; 2024 Mar; 384():e076962. PubMed ID: 38479774
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.
    Lee JN; Kim MY; Kang JH; Kang JK; Chung JW; Ha YS; Choi SH; Kim BS; Kim HT; Kim TH; Yoo ES; Kim SH; Kwon TG
    Investig Clin Urol; 2024 Mar; 65(2):132-138. PubMed ID: 38454822
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Assessment of the Surgical Oncology Case Volume Within the Public Sector in Tanzania.
    Brand NR; Akoko L; Kotecha V; Mwakyembe T; Mwashambwa M; Hamid R; Hando D; Komba C; Mwanga A; Mbele P; Itule P; Jackson J; Misidai M; Gaskill C; Ozgediz D
    JCO Glob Oncol; 2024 Mar; 10():e2300316. PubMed ID: 38452305
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis.
    Dall CP; Mason JB; Goldman CC; Fabrizio G; Alagha EC; Chou J; Kowalczyk KJ; Agarwal PK; Stamatakis L; Krasnow RE
    Urol Oncol; 2024 May; 42(5):121-132. PubMed ID: 38418269
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 238.